BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1-Reference-Cited by-同舟云学术

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

Published:2017-02 Issue:9 Volume:18 Page:2162-2174
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Hogg Simon J.,Vervoort Stephin J.,Deswal Sumit,Ott Christopher J.,Li Jason,Cluse Leonie A.,Beavis Paul A.,Darcy Phillip K.,Martin Benjamin P.,Spencer Andrew,Traunbauer Anna K.,Sadovnik Irina,Bauer Karin,Valent Peter,Bradner James E.,Zuber Johannes,Shortt Jake,Johnstone Ricky W.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference31 articles.

1. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer;Barrett;Oncotarget,2015

2. MYC regulates the antitumor immune response through CD47 and PD-L1;Casey;Science,2016

3. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies;Christiansen;Proc. Natl. Acad. Sci. USA,2011

4. Breakthrough of the year 2013. Cancer immunotherapy;Couzin-Frankel;Science,2013

5. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia;Dawson;Nature,2011

Cited by 246 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cells;Neoplasia;2024-11

2. Cancer plasticity in therapy resistance: Mechanisms and novel strategies;Drug Resistance Updates;2024-09

3. Ring Transformation of Cyclopropenes to Benzo‐Fused Five‐Membered Oxa‐ and Aza‐Heterocycles via a Formal [4+1] Cyclization;Advanced Science;2024-08-29

4. Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor);2024-07-29

5. Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance;Cell Communication and Signaling;2024-06-19